Compare Regeneron Pharmaceuticals Inc (REGN) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vital Farms Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Vital Farms Inc trades at $9.89 (market cap $432.32M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 193× Vital Farms Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| REGN | VITL | |
|---|---|---|
Market Cap | $83.43B | $432.32M |
Sector | Health | Consumer Staples |
52-Week High | $852.03 | $48.56 |
52-Week Low | $555.51 | $8.28 |
Enterprise Value | $78.14B | $519.33M |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Vital Farms (VITL) trades at $10.08, up 1.61% on the day, but faces bearish technical signals with key support at $9. The company reported a challenging Q2 2026 with a net loss per share of $0.47, though revenue of $166 million slightly beat expectations. Gross margin collapsed to 6.6% amid industry oversupply, but management reaffirmed full-year guidance and secured a $125 million term loan for stability.
The outlook is cautious; analyst consensus is a Buy with a $13.00 price target, but near-term risks include persistent margin pressure, cash burn, and competitive pricing gaps. Long-term recovery depends on execution against guidance and market stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
